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Summary 
Lupus anticoagulants (LAC) consist of antiphospholipid anti-
bodies, detected via their anticoagulant properties in vitro. Strong 
LAC relate to thromboembolic events, a hallmark of the anti-
phospholipid syndrome. We have analyzed whether detection of 
this syndrome would benefit from thrombin generation 
measurements. Therefore, calibrated automated throm-
bography was done in normal plasma (n=30) and LAC patient 
plasma (n=48 non-anticoagulated, n=12 on oral anticoagulants), 
diluted 1:1 with a normal plasma pool. The anti-β2-glycoprotein 
I monoclonal antibody 23H9, with known LAC properties, de-
layed the lag time and reduced the peak height during thrombin 
generation induction in normal plasma dose-dependently 
(0–150 μg/ml). At variance, LAC patient 1:1 plasma mixtures 
manifested variable lag time prolongations and/or peak height 
reductions. Coupling these two most informative thrombin gen-
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eration parameters in a peak height/lag time ratio, and upon nor-
malization versus the normal plasma pool, this ratio distributed 
normally and was reduced in the plasma mixtures, for 59/60 
known LAC plasmas. The normalized peak height/lag time ratio 
correlated well with the normalized dilute prothrombin time, di-
luted Russell’s viper venom time and silica clotting time, 
measured in 1:1 plasma mixtures (correlation coefficients 
0.59–0.72). The anticoagulant effects of activated protein C 
(0–7.5 nM) or 23H9 (0–150 μg/ml), spiked in the 1:1 LAC plas-
ma mixtures were reduced for the majority of patients, compat-
ible with functional competition between patient LAC and acti-
vated protein C and LAC and 23H9, respectively. Hence, the nor-
malized thrombin generation-derived peak height/lag time ratio 
identifies LAC in plasma with high sensitivity in a single assay, ir-
respective of the patient’s treatment with oral anticoagulants. 
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Introduction 
The antiphospholipid syndrome (APS) is characterized by the 
occurrence of thrombosis in patients with so-called antiphosp-
holipid antibodies. These antibodies are directed to plasma pro-
teins with affinity for anionic phospholipids. Those antibodies 
with anticoagulant properties in vitro, are referred to as lupus 
anticoagulants (LAC) (1, 2). 
 Antiphospholipid antibodies develop both to proteins with or 
without known function in coagulation. Prothrombin (a repre-
sentative of the former) and β2 glycoprotein I (β2GPI, a represen-
tative of the latter) appear to be the major, but not exclusive 
antigen targets, implicated in the pathophysiology of APS (3). 
Anti-β2-GPI antiphospholipid antibodies promote binding of 
stable bivalent antibody-β2-GPI complexes to phospholipids, re-
sponsible for the anticoagulant effect in vitro (4). Anti-β2-GPI 
antibodies are thrombogenic in animal models (5) and high-avid-
ity anti-β2-GPI antibodies highly correlate with thrombosis in 
men (6). Whereas anti-β2-GPI antibodies are associated with 
thromboembolic complications (1–3), the role of anti-prothrom-
bin antibodies in thrombosis is more controversial (7). Yet, anti-
prothrombin and anti-β2-GPI antibodies co-exist in APS and 
circulating prothrombin-anti-prothrombin complexes were dem-
onstrated in LAC patients (2, 8). 
 Several mechanisms may explain the thrombogenic effects of 
antiphospholipid antibodies. Dimerized β2-GPI supports platelet 
adhesion and aggregation under venous conditions, phenomena 
depending on its interaction with platelet receptors GPIbα and 
apolipoprotein E receptor 2’ (9). Recently, antiphospholipid anti-
bodies were found to interfere with the anticoagulant activity of 
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annexin A5 (10) and of activated protein C (APC) (3). Thus, anti-
body-β2-GPI complexes may compete with components of the 
APC complex for the limited number of binding sites on the 
phospholipid surface, or, alternatively, disrupt the APC complex 
(3). Antibody-β2-GPI complexes can also disturb other phos-
phatidylserine dependent coagulation pathways, including neu-
tralization of activated FX and inhibition of coagulation initi-
ation by tissue factor pathway inhibitor (3). APC inhibition by 
antiphospholipid antibodies potentially also occurs via β2-GPI-
independent mechanisms, such as by antibody-prothrombin 
complexes, competing with APC for binding to phospholipids, 
during inactivation of factor (F)Va or FVIIIa.  
 Recently, global plasma coagulation tests are being applied 
progressively to monitor overall coagulation. Hence, thrombin 
generation allows the recording of a thrombogram, via a high 
throughput approach, with acceptable experimental error, using 
a fluorogenic thrombin substrate and continuous calibration in 
each individual sample (11). The use of calibrated automated 
thrombography allows definition of several thrombin generation 
parameters, such as the lag time, time-to-peak, endogenous 
thrombin potential and peak height. A recent study found that 
supplementing pooled normal plasma with immunglobulins 
from LAC patients induces a wide range of enhancing or in-
hibitory effects on the endogenous thrombin potential (12). We 
have, therefore, investigated via thrombin generation measure-
ments in the plasma of LAC patients whether calibrated auto-
mated thrombography has added value in the diagnosis of APS. 
As part of this characterization, thrombin generation parameters 
were determined in the presence of APC (13) and upon addition 
to plasma of the strong LAC-positive monoclonal anti-β2-GPI 
antibody 23H9 (4). Analytical criteria were defined for the de-
tection of APS, also in patients on oral anticoagulants, in an ef-
fort to facilitate the currently established laboratory diagnostic 
criteria for APS, via use of a single integrated test. 
Materials and methods 
Subject selection and plasma collection 
A control population consisted of plasma from healthy adult vol-
unteers (n=30). Patients were selected from individuals referred 
to our thrombophilia centers or referred for autoimmune disease 
testing. Peripheral venous blood and plasmas were collected, as 
recently described (13) from patients, referred for LAC screen-
ing. After LAC analysis, all samples were kept at –80°C, until 
further analysis. Plasmas were also collected from known LAC-
positive patients, prior to (n=48) or during (n=12) anti-vitamin K 
antagonist (VKA) therapy. As controls for those patients on VKA 
therapy, additional plasma samples (n=9) were collected from pa-
tients on long-term anticoagulant therapy, but negative for LAC; 
their international normalised ratio (INR) values ranged from 
2.05–3.05. A normal plasma pool was made, by mixing equal vol-
umes of plasma from healthy individuals (n=40). Permission to 
analyze patient samples was given by the Ethical Committees of 
the Ghent and Leuven University Hospitals. 
 Persistent LAC were defined, according to the revised ISTH 
Sapporo criteria, as LAC-positivity on at least two occasions, at 
least 12 weeks apart (2). Transient LAC patients were positive on 
a first and negative on a second occasion. Thrombotic episodes 
or pregnancy morbidity were retrospectively identified upon 
consultation of medical records. Paediatric samples were ex-
cluded from analysis, since normal values differ between adults 
and children (13).  
Automated measurement of thrombin generation 
Thrombin generation was triggered in platelet-poor plasma in 
the presence of an intermediate concentration of tissue factor 
(5 pM) and a relatively high concentration of phospholipids 
(4 µM). In these conditions, thrombin generation depends to a 
small degree on FVIII and FIX but not on FXI and is phos-
pholipid-controlled, at concentrations too low to trigger contact 
activation (14). Thrombin generation was performed in normal 
plasma, in the normal plasma pool and in 1:1 mixtures of patient 
plasma and normal plasma pool, in the presence of 1 μM phos-
pholipids, to raise the phospholipid dependence of the assay. The 
tissue factor concentration was 5 pM. Calibrated Automated 
Thrombography® was performed as recently reported (13). Ex-
periments were done in triplicate (controls) or duplicate (pa-
tients) and lag time, peak height of thrombin formation, time to 
peak and endogenous thrombin potential (14) were analyzed. 
Thrombin generation was also performed in the presence of 
human APC (0–7.5 nM, Rossix, Mölndal, Sweden), spiked in 
normal plasma pool and in plasma of all 48 non-anticoagulated 
and of 12 LAC-positive anticoagulated patients. To this end, pa-
tient samples were mixed 1:1 with normal plasma pool. The anti-
coagulant effect of APC was expressed as the APC-ratio = [(peak 
height/lag time without APC) – (residual peak height/lag time 
with APC)]/[peak height/lag time without APC]. The APC-ratio 
expresses thrombin generation inhibition, relative to thrombin 
generation, in the absence of APC. The APC-ratio, determined in 
the 1:1 plasma mixtures was then compared to that measured for 
normal pooled plasma, to evaluate the patient antibody-induced 
resistance to APC. 
 Thrombin generation was also studied in normal plasma 
pool, in normal and patient plasmas, in the presence of the potent 
LAC monoclonal anti-β2-GPI domain 2 antibody 23H9 (0–150 
μg/ml) (4). The 23H9-induced dimerization of β2-GPI mimics 
the effect of patient antibody-β2-GPI complexes (4). For those 
experiments, where 23H9 was added to 1:1 plasma mixtures, the 
anticoagulant effect of 23H9 was expressed as the 23H9-ratio = 
[(peak height/lag time without 23H9) – (residual peak height/lag 
time with 23H9)]/[peak height/lag time without 23H9]. This 
ratio expresses thrombin generation inhibition, relative to throm-
bin generation, in the absence of 23H9. The 23H9-ratio was then 
compared to that measured for normal pooled plasma, to evalu-
ate the patient antibody-induced resistance to 23H9. 
 Alternative thrombin generation measurements were per-
formed in a purified system, with the prothrombin complex con-
centrate PPSB® (prothrombin = FII, proconvertin = FVII, Stuart-
Prower-Factor = FX, and antihemophilic globulin B = FIX from 
CLB, Amsterdam, The Netherlands). 
Routine measurements  
Screening for deficiency of antithrombin, protein C (functional), 
protein S (free antigen), activated protein C resistance and the 
prothrombin gene GA20210 mutation was carried out using 
standard methods (15).  
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Lupus anticoagulant assays  
Plasmas were qualified as LAC-positive, by considering the 
ISTH-citeria in a four-step procedure (16). Samples normal in 
all LAC-sensitive screening tests are reported as LAC-
negative, without further mixing or confirmation testing. 
Samples with prolonged screening test results were further 
analyzed via mixing and confirmation tests. As screening as-
says, a sensitive activated partial thromboplastin time (aPTT) 
(PTT-LA, Diagnostica Stago, Asnières, France), in com-
bination with the diluted Russell’s viper venom time (dRVVT) 
(LA-screen, Gradipore Ltd., Australia), or a dilute prothrom-
bin time (dPT) (Dade Innovin®, Dade Behring, Marburg, Ger-
many) in combination with a dRVVT (LAC-screen, Instru-
mentation Laboratories, Lexington, MA, USA) and silica clot-
ting time (SCT) (Instrumentation Laboratories) were used. 
Finally, a heparin sensitive thrombin time was performed to ex-
clude samples with prolonged screening tests, due to heparin, 
before further LAC testing and specific coagulation factor do-
sage was performed to confirm or exclude factor deficiency, 
due to VKA treatment (17).  
 Mixing studies were done when screening tests were pro-
longed. Reference values were calculated as described and were 
confirmed by retrospective receiver-operator characteristics 
(ROC) analysis (2, 17). We performed mixing tests in a 1:1 ratio 
with normal plasma pool (17). In samples with less than 70% 
correction for at least one mixing test or a positive Rosner index, 
the presence of an inhibitor was concluded (18). To correlate 
thrombin generation parameters and mixing tests, mixing tests 
were expressed as the ratio between the clotting times of the 
mixed patient plasma and the clotting time of a normal plasma 
(pool, when indicated), analyzed in the same run. Likewise, 
thrombin generation parameters were normalized by division of 
the results for the 1:1 plasma mixtures and those measured for 
the plasma pool.  
 Confirmatory tests were done by aPTT (Staclot-LA, Diag-
nostica Stago), dRVVT (LA-confirm, Gradipore Ltd.), dPT and 
SCT, as described (17). Interpretation of the confirmatory tests 
is based on the comparison of clotting times by testing the 
sample in a phospholipid insensitive coagulation assay and by 
repetition of the clotting time after addition of extra phos-
pholipids. Since there are no guidelines to interpret confirmation 
tests, own cut-off values were calculated and compared to litera-
ture data (2, 19). Samples with a positive screening test, a mixing 
test result compatible with the presence of an inhibitor and a 
positive confirmation test in at least one test system are reported 
as positive in this study.  
Figure 1: Anticoagulant properties of 
23H9 and APC in thrombin generation. 
Individual thrombograms, as a function of the 
indicated concentrations of 23H9, added to 
normal plasma (A, B) and of APC (B), initiated 
by 5 pM tissue factor and 4 µM of a phosphati-
dylcholine (PC) and phosphatidylserine (PS) 
mixture (PC/PS: 7/3). 
A 
B 
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Statistical analysis 
Data were analysed using MedCalc® Version 7.1.0.0 (MedCalc 
Software, Mariakerke, Belgium). Comparison of results and cor-
relation analysis were done using Pearson’s correlation and lin-
ear regression analysis. Results were presented as Box-and-
Whisker plots or histograms.  
Results  
Monoclonal anti-β2-GPI antibody 23H9 in thrombin 
generation 
First, the anticoagulant properties of the LAC-positive antibody 
23H9 (0–150 µg/ml) were investigated in thrombin generation, 
upon its spiking in pooled normal plasma. When thrombin gen-
eration was triggered by 5 pM tissue factor and a standard phos-
pholipid concentration (4 µM), 23H9 prolonged the lag time in a 
concentration-dependent manner, approximately two-fold in the 
presence of 100 µg/ml 23H9, and slightly more at 150 µg/ml 
(Fig. 1). At the same time, at 100 µg/ml 23H9, the peak height of 
the thrombogram was reduced by about 30%. Figure 1B also 
shows how the addition of APC to plasma reduces thrombin gen-
eration (via degradation of coagulation cofactors Va and VIIIa). 
23H9 (100 µg/ml) completely inactivated APC (Fig. 1). Hence, 
in agreement with recent data (20–22), 23H9-β2GPI antibody 
complexes strongly interfered with the anticoagulant activity of 
APC, during calibrated automated thrombography. 
 In a reconstituted system of thrombin generation, consisting 
of phospholipids (4 µM), the coagulation factor concentrate 
PPSB (1/400 final dilution) and added purified β2-GPI (150 
µg/ml), the separately added β2-GPI or 23H9 had no effect. In 
combination, they retarded lag time up to two-fold and reduced 
peak height up to 40%, for [23H9] = 50–100 µg/ml (not shown), 
confirming that the anticoagulant effect of 23H9 resulted from 
complex formation with β2-GPI. 
Figure 2: Identification of thrombin gen-
eration parameters in 23H9-induced 
APS. Individual line diagrams for the four 
major thrombin generation parameters indi-
cated in the y-axes, measured in the plasma of 
30 healthy controls, before and after addition 
of 150 µg/ml 23H9, as indicated (ETP: endo-
genous thrombin potential). 
A B 
C D 
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 The anticoagulant effect was most potent at 150 µg/ml 23H9. 
Therefore, the anticoagulant effect of 150 µg/ml 23H9 was ana-
lyzed for all thrombin generation parameters in 30 healthy donor 
plasmas (Fig. 2). Inhibition resulted in a significant prolongation 
of the mean lag time (2.5 ± 0.33 to 4.6 ± 0.76 min, p< 0.0001) and 
time to peak (5.27 ± 0.78 to 8.3 ±1.34 min, p<0.0001). The mean 
peak height was significantly lowered (360.6 ± 75.6 to 272.7 ± 
58.8 nM thrombin, p< 0.0001). The mean endogenous thrombin 
potential was not significantly influenced (2771 ± 444 to 2037 ± 
432 nM thrombin.min) and was even raised by 23H9 in some 
samples (Fig. 2). Because in all normal individuals (n=30), the 
lag time and peak height was significantly affected by 23H9, 
these two parameters were combined in a single index. Indeed, 
the peak height/lag time ratio was affected more (145.8 ± 36.4 to 
61.77 ± 20.3 nM thrombin/min, p<0.0001) by 23H9 than each 
thrombin generation parameter separately. This index was, there-
fore, applied as a measure of the LAC effect in plasma (see 
below). 
Figure 3: Interference on the thrombo-
gram profile between 23H9 and LAC in 
plasma from APS patients. Individual 
thrombograms, as a function of added 23H9, at 
the indicated concentrations, initiated by 5 pM 
tissue factor, supplemented with 4 µM PC/PS, 
in plasma samples of a transiently LAC-positive 
patient (A) and of two LAC-positive patients 
with evidence of thrombosis (B, C). 
A 
B 
C 
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Patient antibody-23H9 interference 
The activity of APC was inhibited by 23H9. To investigate 
whether the anticoagulant activity of 23H9 and that of patient 
antibodies were mutually exclusive, thrombin generation was 
measured in the plasma of LAC-positive patients, upon spiking 
with 23H9 (0–150 µg/ml). Figure 3 shows a series of thrombo-
grams, upon addition of 23H9. For a transiently positive patient 
without thromboembolic complications, additive effects were 
noted for 23H9, at the time where she was LAC-positive (Fig. 
3A). When she had become LAC-negative, the response to 23H9 
had normalized (not shown), a tendency confirmed for other 
transiently positive patients. 
 In contrast, in patients with persistent LAC and evidence of 
thrombosis, 23H9 reacted strongly and with divergent types of 
response. In the example of Figure 3B, low [23H9] disrupted 
anticoagulant immune complexes, shortening lag time and nor-
malizing peak height. Increasing [23H9] then restored the ex-
pected effect for 23H9, i.e. doubling the lag time, accompanied 
by an almost halving of the peak height (Fig. 3B). Finally, Figure 
3C shows the thrombogram for a strongly LAC-positive plasma, 
with demonstrated anti-prothrombin antibodies. The strongly re-
tarded lag time and reduced peak height in this patient were inter-
fered with by 23H9 in a more complex reactivity pattern, in 
which low [23H9] compromise thrombin formation further, but 
higher concentrations increasingly restored it. In another sample 
of the same patient, taken seven weeks later, lag time and peak 
height equalled 13 min and 190 nM thrombin, respectively, but 
high [23H9] only mildly reduced thrombin formation (not 
shown). These findings illustrate the large interindividual vari-
ation and fluctuations over time in antibody titers and manifes-
tation in LAC-positive patients, probably reflecting heteroge-
neity of implicated antigens, epitopes and antibody concen-
tration. Nevertheless, they illustrated that, similarly to APC, 
23H9 was a useful reagent in the study of the anticoagulant prop-
erties of patient LAC, when tested at relevant concentrations.  
Thrombin generation in LAC patient plasmas: 
Analytical conditions 
We have investigated whether lowering the phospholipid con-
centration in the plasma sample would raise the sensitivity of the 
LAC-detection via calibrated automated thrombography. Figure 
4A shows that in normal plasma, the peak height is proportional 
to the concentration of PC/PS and that the relative effect of 
100 µg/ml 23H9 on thrombin generation improved at PC/PS con-
centrations below 4 µM. Because thrombin generation was too 
much compromised at 250 nM, the further analysis of patient 
samples was carried out at 1 µM PC/PS, together with tissue fac-
tor, at 5 pM. Figure 4B and C confirm that the same effect was 
observed in LAC patient plasma, spiked with 100 µg/ml 23H9, 
i.e. peak height and lag time were more affected by 23H9 at 
1 µM than at 4 µM. Therefore, subsequent thrombin generation 
measurements were done in the presence of 1 µM PC/PS.  
Plasma characteristics of anticoagulated and non- 
anticoagulated LAC patients 
We wanted to determine whether thrombin generation has value 
in LAC-detection in plasmas from patients, including those on 
oral anticoagulants. Therefore, 48 non-anticoagulated and 12 
anticoagulated LAC-positive plasmas were selected. The nor-
malized dPT, dRVVT and SCT distribution in screening, confir-
mation and mixing tests of the selected samples is shown in de-
tail in Figure 5, for both categories of patient samples. The 
dRVVT has the highest sensitivity in LAC screening, mixing and 
confirmation tests; a positive dRVVT mixing test for the patients 
on oral anticoagulants illustrates that these samples were LAC-
positive (Fig. 5). When both patient categories were compiled, 
Table 1 confirms that all patients were LAC-positive and that the 
dRVVT has the best overall sensitivity for the LAC-detection, ir-
respective of the anticoagulant treatment status of the patient. 
Before investigating in LAC-positive plasma samples 
whether thrombin generation could be performed in plasma from 
patients on oral anticoagulants, we have evaluated whether 1:1 
mixing of LAC-negative plasma from patients on oral anticoagu-
lants (n=9) with normal plasma would normalize the anticoagu-
lant properties of such plasma. Figure 6A shows how the mixing 
procedure almost normalized the peak height/lag time index in 
the 1:1 plasma mixtures (mean peak height/lag time around 80 
nM thrombin/min), compared to the normal plasma pool (around 
100 nM thrombin/min). When these tests were done in the pres-
ence of 23H9 (100 µg/ml) and/or APC (3.75 nM) (Fig. 6A), the 
same degree of inhibition was found in the mixtures as in the nor-
mal plasma control, whereas 23H9 inhibited APC, as expected. 
Hence, the 1:1 mixing procedure appeared to almost completely 
correct the effects of the oral anticoagulants and 23H9 and APC 
affected the peak height/lag time ratio in these mixtures, to the 
same degree as in normal plasma. 
Therefore, these analytical conditions were applied for the 
analysis of the 60 confirmed LAC-positive patients. Figure 6B 
shows the normalized results for lag time, peak height and peak 
height/lag time ratio, measured in 1:1 plasma mixtures, for the 
48 non-anticoagulated and 12 anticoagulated plasmas, each. 
This representation reveals a similar distribution of values in the 
anticoagulated and non-anticoagulated plasmas. Repetitive de-
termination in the normal plasma pool uncovered a coefficient of 
variation (CV) of 13% (n=8) for the normalized peak height/lag 
time ratio. Consequently, the corresponding cut-off value was 
not set at 1 but at 0.87 (Fig. 6B), revealing a reduced peak height/
lag time ratio in 47/48 non-anticoagulated and 12/12 anticoagu-
lated plasmas. 
This analysis showed that LAC-positive samples could be 
analyzed via thrombin generation, irrespectively of the degree of 
anticoagulation (for INR<3). Hence, Figure 7A shows the nor-
malized thrombin generation parameters, pooled for all 60 
samples. As expected from their prolonged clotting times, all 
samples showed a prolonged lag time (normalized range: 
1.16–18.2; mean ± standard deviation [SD]: 2.7 ± 3; median: 
1.8), but with wide distribution. Although in normal plasma, 
23H9, in addition to prolonging the lag time, produced a con-
comitant dose-dependent reduction of the peak height, the peak 
height was not reduced in all plasma samples (normalized range: 
0.01–1.2; mean ± SD: 0.87 ± 0.25; median: 0.93). This analysis 
excludes an automatic coupling between lag time prolongation 
and peak height reduction, in agreement with our finding that the 
lag time and peak height provide independent information in 
thrombin generation, i.e. do not correlate (not shown). However, 
when combined in a single index, i.e. the peak height/lag time 
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ratio (normalized range: 0.0005–0.93; mean ± SD: 0.5 ± 0.24; 
median: 0.53), this index showed a Gaussian distribution (Fig. 
7A insert), when analyzed according to the D'Agostino-Pearson 
test (p=0.265) and was reduced (<0.87) in 59/60 patients. Com-
parison of the normalized peak height/lag time ratio to the nor-
malised result of mixing studies for dPT, dRVVT and SCT (Fig. 
7B-D) showed correlation coefficients of –0.586 (p<0.0001), 
–0.678 (p<0.0001), –0.715 (p<0.0001), respectively.  
APC in thrombin generation in LAC patient 1:1 plasma 
mixtures 
Analysis in 25 healthy donor plasmas revealed 51 ± 23% in-
hibition of the endogenous thrombin potential and 52 ± 22% in-
hibition of the peak height, by 3.75 nM APC, although slight ad-
justments of this concentration was necessary to maintain about 
50% inhibition of peak height in normal plasma, for APC present 
in different batches. The lag time was hardly affected. Cor-
Figure 4: Phospholipid dependence of 
23H9-induced anticoagulant activity. Indi-
vidual thrombograms, with and without 23H9, 
added at 100 µg/ml, initiated by 5 pM tissue 
factor and measured in the presence of the in-
dicated concentrations of a phosphatidylcho-
line (PC) and phosphatidylserine (PS) mixture 
(PC/PS: 7/3), in a normal plasma pool (A) and 
in LAC-positive plasmas (B, C). 
A 
B 
C 
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respondingly, the mean APC-ratio for normal pooled plasma 
equalled 0.51, with an inter-assay coefficient of variation (CV) 
of 9.1%, therefore with lower and upper limits of 0.46 and 0.56, 
respectively. Hence, an APC-ratio >0.56 corresponds to more in-
hibition by APC, and a value <0.46 to less inhibition, or resis-
tance to APC. We found that of the non-anticoagulated LAC pa-
tients 5/48 (10.4%) manifested an APC-ratio >0.56 and 3/48 
(6.3%) had a ratio between 0.46 and 0.56. However, 40/48 
(83.3%) patients showed an APC-ratio <0.46, i.e. were resistant 
to APC. Only 1/9 anticoagulated LAC plasmas showed an APC-
ratio < 0.46.  
Figure 5: Distribution of the LAC-posi-
tive plasma sample characteristics. Box-
and Whisker plots for normalized screening, 
confirmation and mixing test, as indicated, 
measured in 48 non-anticoagulated (left bar in 
each test, i.e. without OAC) and 12 anticoagu-
lated (right bar in each test, i.e. with OAC) 
plasma samples from randomly selected LAC 
patients. The central box represents the 25 and 
75 percentile and the middle line the median. 
The vertical black line extends from the mini-
mum to the maximum value, outliers being dis-
played as separate points. The red lines repre-
sent the 1 SD group intervals. The blue lines in-
dicate the cut-off value, which are also shown 
in parentheses.  
A 
B 
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23H9 in thrombin generation in LAC patient 
1:1 plasma mixtures 
The 23H9-ratio was determined in the presence of 50 µg/ml 
(non-anticoagulated patient group) or 100 µg/ml (anticoagulated 
patient group) 23H9. The mean 23H9-ratio and inter-assay CV 
of the normal plasma pool were 0.69 (50 µg/ml 23H9) and 0.89 
(100 µg/ml 23H9) and 12.3%, respectively. The lower limit was 
therefore set at 0.61, and the upper limit at 0.77 (50 µg/ml 23H9) 
and at 0.79 and 1, respectively (100 µg/ml). Patients with a 
23H9-ratio higher than the upper limit show an enhanced effect 
for 23H9; a value lower than the lower limit means less effect 
compared to that in the normal plasma pool, i.e. resistance to 
23H9. In the non-anticoagulated LAC plasmas, 1/48 (2.1%), 
10/48 (20.8%) and 36/48 (75%), showed 23H9-ratios >0.77, be-
tween 0.61 and 0.77 and <0.61, respectively. In 3/12 (25%) anti-
coagulated LAC plasmas, a value <0.79 was found; all other pa-
tients were within the range for normal plasma. Or, 75% of the 
non-anticoagulated and 25% of the anticoagulated samples 
showed resistance to 23H9. 
Discussion  
APS is an important cause of acquired thrombophilia. However, 
thrombogenicity assessment in APS patients remains a chal-
lenge. Laboratory tests in APS have poor predictive value for the 
thrombotic phenotype (2), and, in spite of their refinement, the 
test procedures in the laboratory detection of LAC, have essen-
tially not changed over the last 30 years. Diagnosis relies on a 
combination of tests, since no single test has sufficient specifi-
city and sensitivity (2). Therefore, the search for better perform-
ing coagulation assays in LAC testing continues; we presently 
studied whether calibrated automated thrombography can con-
tribute to the diagnosis of APS. Since also thrombin generation 
relies on negative phospholipid surfaces, this study analyzed 
 Screening + confirmation  
+ mixing test 
Screening Mixing Confirmation 
dPT (n=60) 41 (66%) 59 (98%) 54 (90%) 43 (71%) 
dRVVT (n=58) 52 (89%) 58 (100%) 58 (100%) 52 (89%) 
SCT (n=58) 28 (48%) 46 (79%) 29 (50%) 30 (51%) 
 
 
 
 
Table 1: Sensitivity of LAC detection in 
60 LAC-positive antiphospholipid patient 
plasma samples, expressed as positive 
normalized test result during screening, 
confirmation and mixing tests. Results 
were pooled for 48 non-anticoagulated and 
10–12 anticoagulated plasmas.  
Figure 6: Thrombin generation parame-
ters in 1:1 plasma mixtures. Peak height/lag 
time ratios for “normal” plasma or for “mix-
tures” of LAC-negative plasma from patients 
on oral anticoagulants, mixed 1:1 with normal 
plasma pool (A), measured with 5 pM tissue 
factor, at 1 µM phospholipids. The anticoagu-
lant effect of 23H9 (100 µg/ml), APC (3.75 nM) 
and their combination is also shown, in normal 
plasma and the 1:1 plasma mixtures. Box-and 
Whisker plots for the lag time, peak height and 
peak height/lag time ratio, measured in 48 non-
anticoagulated (left bar in each test, i.e. with-
out OAC) and 12 anticoagulated (right bar in 
each test, i.e. with OAC) plasma samples from 
LAC patients, in 1:1 mixtures with a normal 
plasma pool and after normalization (b); the 
blue lines represents the cut-off values for the 
peak height/lag time ration (0.87). Box parame-
ters are as in Figure 5. 
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whether thrombin generation parameters can reliably diagnose 
LAC in patient plasma, based on the rationale that a single test 
may provide more accurate information than the multitude of 
clotting assays required in LAC testing, today (23, 24).  
 Previous thrombin formation tests by a chromogenic assay in 
APS patients showed inhibition of thrombin generation in the 
presence of anti-β2GPI antibodies (25, 26). This inhibition 
strongly correlated with a history of clinical manifestations (26). 
Thrombin generation in platelet-poor plasma seemed less sensi-
tive to LAC than measurements in platelet-rich plasma, since the 
endogenous thrombin potential was only inhibited in part of the 
patients (12). Our present findings confirm, upon addition to 30 
normal plasmas of the LAC monoclonal anti-β2GPI antibody 
23H9 (4), that not all plasmas responded with an inhibition of 
this parameter. We found that rather lag time and peak height are 
the parameters of choice to monitor the anticoagulant effect of 
antiphospholipid antibodies.  
When tested in β2-GPI antibody ELISAs, only a minority of 
our LAC patient samples tested positive (data not shown), ques-
tioning the sensitivity of such assays. In contrast, during throm-
bin generation in 1:1 plasma mixtures, either their plasma peak 
height (thrombin concentration) was lowered or their lag time 
delayed, or both. The prolongation of the lag time is not surpris-
ing, in view of the anticoagulant effect of LAC in the various 
clotting assays performed to select our patient plasmas. Yet, in 
line with previous reports, thrombin generation parameters 
showed large intra-individual variations in the control group (13, 
14), even larger in the patient LAC populations, reflecting the 
heterogeneity of LAC (12). In addition, not all LAC patients sim-
ultaneously manifested lag time prolongation and peak height 
reduction. This can be understood by the existence of initiation 
and propagation pathways of coagulation and potential interfer-
ence by antiphospholipid antibodies with each phase, indepen-
dently (11). Combining the independent information measured 
in the peak height (with reduced nominator) and the lag time 
(with enlarged denominator) in a ratio, seems a more powerful 
parameter for the detection of LAC patients because it contains 
more information than the lag time per se. This ratio was affected 
in all patient samples studied and was more normally distributed 
throughout the patient population tested than the lag time. 
In relation to their thrombogenic risk, the assessment of 
LAC-activity is the best test in the detection of antiphospholipid 
antibodies (27). However, all coagulation tests for LAC are pro-
longed by oral anticoagulants, as well as by heparin. The current 
guidelines recommend to dilute patient plasma with normal 
plasma, at INR values above 3 (2). Evaluation of this strategy 
during thrombin generation measurements in 1:1 mixtures of 
anticoagulated patient plasma and normal plasma, showed that it 
effectively neutralized anticoagulant effects. To raise the sensi-
tivity of the assay, recommended phospholipid concentrations 
Figure 7: Relation between normalized 
peak height/lag time ratio and normal-
ized mixing test results. Box-and Whisker 
plots for the lag time, peak height and peak 
height/lag time ratio, for all 60 LAC-positive 
patients, in 1:1 mixtures with normal plasma 
and after normalization (A); the insert shows 
the normalized peak height/lag time distribu-
tion histogram for these samples. Linear re-
gression analysis of normalized peak height/lag 
time ratios for LAC plasmas, mixed 1:1 with a 
normal plasma pool (n=60) versus the normal-
ized result in mixing tests for dRVVT (B), dPT 
(C) and SCT (D). Thin lines represent calcu-
lated 99% percentile cut-off values for all pa-
rameters (0.87 in TG, 1.1 in dPT, 1.1 in dRVVT 
and 1.2 in SCT), respectively; corresponding 
Pearson correlation coefficients r with 95% 
confidence interval are –0.586 (-0.733 to 
–0.387) (p<0.0001, A), –0.678 (-0.797 to 
–0.509) (p<0.0001, B) and –0.715 (-0.821 to 
–0.560) (p<0.0001, C). Box parameters are as 
in Figure 5. 
A B 
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were lowered to 1 µM. Following this strategy, and upon taking 
into account inter-assay variation, 59/60 (98%) selected LAC 
plasmas showed reduced normalized peak height/lag time ratios, 
irrespective of the intake of oral anticoagulants. A good cor-
relation was found between the peak height/lag time ratio and the 
results of classical mixing tests, which are a part of the current 
three-step procedure for LAC testing. Furthermore, 59/60 pa-
tients were positive for both the normalized peak height/lag time 
ratio (<0.87) test and the mixing test on dRVVT (>1.1). The one 
patient with a high peak height/lag time ratio (0.93) comparable 
to that for normal plasma, was positive for all three classical mix-
ing studies. These data suggest that a double assessment of LAC 
activity by thrombin generation and dRVVT in 1:1 mixed plasma 
samples may identify all APS patients, independently of their 
oral anticoagulant treatment status. They suggest a place for 
thrombin generation in diagnosis and monitoring of APS.  
Our findings illustrated that LAC plasmas from thromboem-
bolic patients contained potent anti-β2-GPI antibodies (even 
when not detected by currently used ELISAs), interfered with by 
23H9 to a different degree from patient to patient, both quali-
tatively and quantitatively. Also, the mixing studies revealed a 
decreased response to a fixed concentration of added 23H9, in 
75% of the non-anticoagulated LAC plasmas. However, in the 
anticoagulated group, 75% of the LAC-positive patients re-
sponded to 23H9 similarly as normal plasma. This confirmed 
what we observed in individual patients: antibody titers change 
with time. Acquired resistance to APC is a common feature of 
APS and may be independent of the presence of anti-β2GPI anti-
bodies (28). Important resistance to the activity of the protein C 
system in the presence of LAC was demonstrated by throm-
bography before (21, 22). Regnault et al. only observed resis-
tance to thrombomodulin (TM) and APC in the presence of phos-
pholipids from the patient’s platelets but not necessarily with 
phospholipids added to platelet-poor plasma, such as applied 
presently. Here, in 83% of the non-anticoagulated LAC plasmas, 
we observed resistance to APC, but this proportion was much 
lower in anticoagulated LAC plasmas. This finding substantiates 
the conclusion that antibody titers change with time. Measuring 
and reporting a more precise index would, therefore, allow more 
quantitative monitoring, i.e. co-define the need for sustained 
anticoagulant therapy, in relation to the titer of antiphospholipid 
antibodies in patient plasma. The peak height/lag time ratio may 
provide such a sufficiently quantitative parameter to monitor 
APS, also during anticoagulant therapy.  
So far, available information suggests that the laboratory 
measurement of thrombin production and activity in patients at 
risk for and in patients with significant thrombosis, does not pro-
vide information useful for clinical decision-making (29). Yet, 
our present analysis of the peak height/lag time ratio in patient 
samples and in 1:1 plasma mixtures shows that thrombin gener-
ation, in association with dRVVT is highly informative in the 
laboratory detection and monitoring of LAC.  
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What is known about this topic? 
– Diagnosis of the antiphospholipid syndrome requires a 
multitude of laboratory tests. 
– The laboratory diagnosis is only qualitative. 
What does this paper add? 
– Thrombin generation can detect the antiphospholipid syn-
drome in a single test. 
– Normalization and definition of an index, defined as the 
ratio between the peak height and the lag-time allow to 
express the patient's antibody anticoagulant potency. 
– The peak height/lag time ratio can be measured for 1:1 
mixtures of normal plasma and plasma from patients on 
anticoagulant treatment.
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